Core Scientific Inctx
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
CORZ$12.72+8.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except par value)
| December 31,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current Assets: | ||
| Cash and cash equivalents | $836,197 | $50,409 |
| Restricted cash | 783 | 19,300 |
| Accounts receivable | 1,025 | 1,001 |
| Digital assets | 23,893 | 2,284 |
| Prepaid expenses and other current assets | 42,064 | 24,022 |
| Total Current Assets | 903,962 | 97,016 |
| Property, plant and equipment, net | 556,342 | 585,431 |
| Operating lease right-of-use assets | 114,472 | 7,844 |
| Other noncurrent assets | 24,039 | 21,865 |
| Total Assets | $1,598,815 | $712,156 |
| Liabilities and Stockholders’ Deficit | ||
| Current Liabilities: | ||
| Accounts payable | $19,265 | $154,751 |
| Accrued expenses and other current liabilities | 69,230 | 179,636 |
| Deferred revenue | 18,134 | 9,830 |
| Operating lease liabilities, current portion | 9,974 | 77 |
| Finance lease liabilities, current portion | 1,669 | 19,771 |
| Notes payable, current portion | 16,290 | 124,358 |
| Total Current Liabilities | 134,562 | 488,423 |
| Operating lease liabilities, net of current portion | 97,843 | 1,512 |
| Finance lease liabilities, net of current portion | 3 | 35,745 |
| Convertible and other notes payable, net of current portion | 1,073,990 | 684,082 |
| Contingent value rights | 4,272 | — |
| Warrant liabilities | 1,097,285 | — |
| Other noncurrent liabilities | 11,040 | — |
| Total liabilities not subject to compromise | 2,418,995 | 1,209,762 |
| Liabilities subject to compromise | — | 99,335 |
| Total Liabilities | 2,418,995 | 1,309,097 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ Deficit: | ||
| Preferred stock; $0.00001 par value; 2,000,000 and nil shares authorized at December 31, 2024 and December 31, 2023, respectively; none issued and outstanding at December 31, 2024 and December 31, 2023 | — | — |
| Common stock; $0.00001 and $0.0001 par value at December 31, 2024 and December 31, 2023, respectively; 10,000,000 shares authorized at December 31, 2024 and December 31, 2023; 292,606 and 386,883 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | 3 | 36 |
| Additional paid-in capital | 2,915,035 | 1,823,260 |
| Accumulated deficit | (3,735,218) | (2,420,237) |
| Total Stockholders’ Deficit | (820,180) | (596,941) |
| Total Liabilities and Stockholders’ Deficit | $1,598,815 | $712,156 |
Certain prior year amounts have been reclassified for consistency with the current year presentation.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.